{‘She has zero expertise’: the US scientific field prepares for Tracy Beth Høeg’s appointment at the Food and Drug Administration.

As the US proceeds with sweeping changes to its vaccine recommendations, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccines throughout the pandemic and has focused upon alleged deaths after Covid vaccination in her brief position at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Program

Health officials planned to unveil radical revisions to the pediatric immunization program in December, aligning the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with much of the world with little proof for benefit. The planned update has been postponed until the coming year.

In place of Vinay Prasad, Dr. Høeg is listed to speak at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

A New Direction at the FDA

The acting appointment might represent a tighter collaboration between the drug and biologics branches as Høeg and Prasad solidify control at the regulatory agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for ending specific childhood vaccine recommendations in the US so as to align more in line with Denmark's approach, a country with comprehensive healthcare and a population approximately the size of Wisconsin’s.

To date statements, she has kept her attention on vaccination policy – traditionally the purview of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious track record in pharmaceutical research, oversight or administrative roles, which has been customary for former heads of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for overseeing the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Former heads of the center would “understand laws and regulations and the science of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who led the center have had.”

CDER has an immense range of responsibilities at the agency, Woodcock pointed out.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and all of those must be managed,” Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant administrative element to the position, which supervises in excess of 5,000 employees. “It’s a huge administrative position, if you perform it correctly,” the former official added.

Agency Reaction and Controversial Initiatives

In response to concerns about Dr. Høeg's credentials and whether this appointment signifies increased cooperation among agency officials on vaccines, a representative responded that the “concerns are based on incorrect presumptions”.

“Her experience aligns with the duties of her job,” the representative stated, citing the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s new priority voucher program, a controversial one-day drug-approval program that reportedly concerned her former heads. “By what process are these medications being selected for this fast-track system? Who is making the choices?” Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he said, “the FDA looks to be trending towards laxer regulations of all drugs, with the exception of immunizations.”

Public Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if troubling, history, Howard observe. She released a research paper using unverified public submissions to estimate the frequency of myocarditis following COVID-19 immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming government included altering regulations for novel immunizations and ending “optional” immunizations, she stated after the election on a online show. At the agency, Høeg has reportedly suggested preventing teenage boys from getting COVID-19 vaccinations.

“She’s an all-around dogmatist who begins with her preconceived notions and tailors the evidence to retrofit the science in a very misleading, dishonest fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg joined other dissenters, {like|